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Abstract
Background: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs) during the acute/
early phases of infection have been analyzed in depth in many studies. In contrast, little is known about neither the long-
term evolution of the virus in patients who developed broadly Nabs (bNabs) or the mechanism of escape in presence of
these bNabs.
Results: We have studied the viral population infecting a long term non progressor HIV-1 infected patient who had
developed broadly neutralizing antibodies toward all tier 2/3 viruses (6 clades) tested, 9 years after infection, and was then
followed up over 7 years. The autologous neutralization titers of the sequential sera toward env variants representative of
the viral population significantly increased during the follow-up period. The most resistant pseudotyped virus was identified
at the last visit suggesting that it represented a late emerging escape variant. We identified 5 amino acids substitutions that
appeared associated with escape to broadly neutralizing antibodies. They were V319I/S, R/K355T, R/W429G, Q460E and G/
T463E, in V3, C3 and V5 regions.
Conclusion: This study showed that HIV-1 may continue to evolve in presence of both broadly neutralizing antibodies and
increasing autologous neutralizing activity more than 10 years post-infection.
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Introduction
The real impact of the humoral response to the human
immunodeficiency virus type 1 (HIV-1) in the course of infection is
still a matter of debate [1–4]. To date, studies have focused on the
neutralizing response since neutralizing antibodies (Nabs) are
usually deeply involved in protection against viral infections [5,6].
In the context of HIV-1 infection, Nabs appear at the early stage
of the infection in most of the patients but have been described as
ineffective on the long term since they do not seem to be associated
with control of viral replication and disease progression [7].
However, Nabs exert a selective pressure on the viral population,
leading to continuously evolving viral variants that escape
neutralization [8–10]. The initial neutralizing antibody response
is primarily narrow in its spectrum in most individuals (i.e.
autologous neutralization), with heterologous neutralizing anti-
bodies produced in only a fraction of infected individuals later in
infection [4,11,12]. Several years after primary infection, only a
limited percentage of HIV-1 infected patients are able to develop
broadly Nabs (bNabs) albeit it appeared that there was a lack of
effect of bNabs on disease progression [11,13,14]. Some of these
patients were characterized as elite neutralizers due the excep-
tional breadth and potency of their antibodies [15]. A few human
broadly neutralizing monoclonal antibodies have been isolated
from such patients [16–19] and have been shown to be protective
in non-human primate studies [20–23]. Therefore, the identifica-
tion of the epitopes targeted by these bNabs, either monoclonal or
polyclonal present in human sera, is of prime importance in the
perspective of developing an efficient HIV vaccine able to induce
protective antibodies [24,25].
The viral evolution and immune escape experienced by the
virus during the acute/early phases of infection have been
analyzed in several studies [9,10,26–30]. These studies have
documented the antibody response raised early in infection
against the transmitted/founder viruses, the preferentially
transmitted variants being considered as those towards which
a protective response should be induced by an hypothetical
efficient vaccine [31–35]. They showed that the pathway that
HIV-1 uses to escape the early autologous neutralizing response
is not unique, ranging from single amino-acid changes to larger
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deletions/insertions, and is frequently associated with modifica-
tion of N-glycosylation sites (PNGS) that led to the concept of
an evolving glycan shield at the surface of the envelope spikes
[10,36]. In contrast, little is known about the long-term
evolution of the virus in patients who developed bNabs, in
particular the mechanism of escape if HIV-1 continues to
replicate in presence of these bNabs [37–39]. However, this
knowledge is crucial for understanding HIV escape to the most
efficient Nabs, and might be useful to designing an efficient
HIV vaccine. In the present study, we have studied the viral
population infecting a long term non progressor (LTNP) HIV-1
infected patient who had developed bNabs at a level compatible
with an elite neutralizer status after at least 8 years of infection,
over 7 years of follow-up. We provide evidence of continuous
evolution of HIV-1 albeit the presence of bNabs, and describe
the molecular characteristics of this evolution.
Materials and Methods
Ethics Statement
The institutional review board of Pitie´ Salpeˆtrie`re Hospital
(Paris, France) approved the study protocol, and each patient
enrolled in the French LTNP cohort (ALT ANRS CO15)
provided written informed consent.
Nucleic Acid Extraction, Cloning and Sequencing
Genomic DNA was extracted from PBMC using the
QIAamp DNA Blood Midi kit according to the manufacturer’s
instructions (Qiagen, Courtaboeuf, France). A 1276 bp env
fragment encompassing most of the gp120 coding sequence
(from upstream of variable region 1 [V1] to downstream of V5)
was amplified by nested polymerase chain reaction (PCR) using
subtype B env -specific primers as previously described [40]. The
PCR products were inserted into pCR2.1 (Topo TA cloning kit;
Invitrogen, Paisley, UK) and sequenced as described [40]. Sixty-
nine clones were obtained (Table 1). The assigned accession
numbers were EF179881 through EF179896 and JN634878
through JN634933.
Env-pseudotyped Virus Construction
We selected 24 env clones considered to be representative of the
viral genetic diversity present at each sampling time-point among
the 69 clones. The strategy to generate env-pseudotyped viruses
expressing gp120 from each clone was previously described
[41,42]. We used the pCR2.1 vector containing the entire
NL4.3 env gene inserted at the EcoRI site. In a first step, the
NL4.3 env gene was digested using NdeI and MfeI (New England
Biolabs) and the deleted fragment was replaced by each of the
corresponding 24 env selected clones. Then, chimeric env genes
were cloned into the EcoRI site of the pCI expression vector
(Promega). Env-pseudotyped viruses were generated by cotrans-
fecting 36106 293T cells using 4 mg of each pCI-env plasmid and
8 mg of pNL4.3.LUC.R_E_ [43] with the FuGene-6 HD trans-
fection reagent (Roche Applied Science, Indianapolis, IN). Viral
supernatants were collected 48 h later and purified by filtration
(0.45 mM filter) and stored as aliquots at 280uC. Viral infectivity
was monitored by infection of 10,000 TZM-bl cells with 100 mL of
serial 5-fold dilutions of the viral supernatants in quadruplicate in
the presence of 30 mg/mL DEAE-dextran. After 48 h of
incubation, infection levels were determined by measuring the
luciferase activity of cell lysates using the Bright-Glo luciferase
assay (Promega) and a Centro LB 960 luminometer (Berthold
Technologies) [44]. Results with relative light unit (RLU) values
.2.5 times the negative control (blank pCI vector) were
considered positive. Thirteen of the 24 pseudotypes viruses were
infectious, and then used for neutralization studies (Figure 1).
Neutralizing Assays
Patient`05005’s serum was among the very rare samples from
LTNPs at entry in the cohort that was able to neutralize (IC90$10)
all four primary isolates (FRO, GIL, MBA and KON) of four
different clades (B, F, CRF01_AE and CRF02_AG, respectively),
selected for their low sensitivity to neutralization [13]. Breadth of
neutralization was further assessed toward 6 heterologous primary
isolates with top ranking neutralization resistance properties.
These subset included 92BR020, 94UG103, 93IN905, and
92TH021 (clades B, A, C and CRF01_AE, respectively), four
viruses identified as indicators for cross-clade elite neutralization
[15]. The two other viruses were BIG (B) and 92RW020 (A), two
moderately resistant viruses [15,45].
Heterologous neutralization was tested in duplicate using 3-fold
serial dilutions (from 1:20 to 1:540) of the serum samples.
Autologous neutralization experiments were carried out in
duplicate using 3-fold serial dilutions (from 1:40 to 1:87480) of
the serum samples. Briefly, aliquots of 50 mL of the virus dilution
(either primary isolate for heterologous neutralization or pseudo-
typed viruses for autologous neutralization), corresponding to 100
50% tissue culture infectious doses (TCID50), were incubated for
1 h at 37uC with 11 mL of each dilution of heat-inactivated sera.
The mixture was then used to infect 10,000 TZM-bl cells [46,47]
in the presence of 30 mg/mL DEAE dextran. Infection levels were
determined after 48 h by measuring the mean value of luciferase
activity of cell lysates. The IC50 was determined as the reciprocal
serum dilution required to reduce RLUs by 50%.
Neutralization sensitivity of the pseudotyped viruses to the
broadly mabs b12, 2G12, PG9 and PG16 was tested in duplicate
with 3 fold serial dilutions of each mab, starting from 50 mg/mL
(b12 and 2G12) or 10 mg/mL (PG9 and PG16), and following the
same procedure.
Sequences Analyses
Sequence alignments were performed using the MAFFT
multiple-alignment software [48]. Amino acid positions were
identified according to HxB2 numbering. The number of potential
N-glycosylation sites (PNGS) (NX[ST] pattern, where X can be
any amino acid) was determined with the N-Glycosite tool [49].
Non synonymous substitutions (dN) rates, synonymous substitu-
tions (dS) rates and dN/dS ratio within each timepoint for either
global sequences or constant and variable env regions only were
calculated with the HyPhy software using SLAC analysis (http://
www.datamonkey.org/; [50]). Positive selection, neutral evolution
and purifying selection were indicated by dN/dS .1, dN/dS = 1
and dN/dS ,1 respectively. The average evolutionary divergence
between sampled sequences and the reconstructed ancestor
sequence was estimated using TreeStat v1.6.1 (http://tree.bio.
ed.ac.uk/software/treestat/). Analysis of viral diversity among the
sixty-nine sequences was performed using the Entropy-One
software (http://www.hiv.lanl.gov/content/sequence/
ENTROPY/entropy_one.html). Net charges of gp120 were
calculated by counting the overall number of charged amino-
acids residues per sequence, considering R and K= +1,
H= +0.293, D and E as 21. The sequences were screened for
recombination breakpoints using the genetic algorithm for
recombination detection (GARD) [51]. Positively selected codons
were identified using Bayes Empirical Bayes (BEB) analysis
implemented in the program codeML, from the PAML package
[52]. To detect selection, alignments were fitted to the NSsites
models M7 (neutral model, codon values of dN/dS fit to a beta
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distribution, dN/dS.1 disallowed) and M8 (positive selection
model, similar to M7 but with an extra class of dN/dS.1
allowed). Likelihood ratio tests were performed to assess whether
permitting codons to evolve under positive selection gives a
significantly better fit to the data (model comparisons M7 vs M8).
To maintain confidence in the inferred positively selected codons,
we considered only identified codons with a cut-off posterior
probability of 95%.
Phylogenetic Analysis
The phylogenetic relationship of the 69 env sequences was
reconstructed using several phylogenetic algorithms [24,53]. We
first reconstructed the sequences phylogeny by maximum likeli-
hood inference, using the program PhyML implemented in the
SEAVIEW package, under the General Time reversible (GTR)
model of nucleotide substitution. Confidence in the neighbor
joining tree topology with ML distances under a GTR model was
assessed by 1000 bootstrap replicates with SeaView Software
version 4.2.11 [54]. The influence of convergent evolution due to
selective pressure on the tree reconstruction was assessed by
repeating the analysis with third codon positions only (417 nt), and
after removing 33 codons identified as positively selected.
Following the identification of 2 recombination breakpoints along
the gene sequence, using the software GARD from the HyPhy
package [51], phylogenies were also reconstructed after partition-
ing the alignment.
In order to estimate divergence times of the viral variants,
Bayesian MCMC dated phylogenies were reconstructed using
the BEAST package [55]. The analysis was conducted under
the best-fitting set of molecular, coalescent and demographic
models, as indicated by a Bayes Factor .20. These comprised
the SRD06 model of nucleotide substitution with separate HKY
with gamma-distributed rate heterogeneity at 1st +2d and 3rd
codon positions, an uncorrelated lognormal molecular clock
model and a Bayesian skyline plot tree prior. Tip dates were
informed with the sampling date of the sequences. The BEAST
analyses were run for 50 million steps, trees sampled every
100th generation, and a maximum clade credibility tree was
selected with the software TREEANNOTATOR, after a 10%
burn in. Trees were visualized and edited in FIGTREE v.1.3.1.
Considering the recombination breakpoints, we also performed
the Bayesian evolutionary analysis after partitioning the
subregions separetely, with linked substitution and clock models,
but unlinked partition trees.
Statistical Analysis
Statistical analyses were performed using the PRISM 5.04
Graphpad software package. Evolution of env glycosylation, net
charges, length of gp120, and length of variable loops were
analyzed using a Pearson correlation test. Neutralization potencies
of the three successive sera were compared by One-way ANOVA
test for repeated measures. The evolution of positively selected
amino-acids over time was assessed by linear regression analysis.
Changes in viral divergence from the founder virus were analyzed
using a Spearman correlation test.
Results
Patient: Clinical and Biological History
Patient 05005, infected by a subtype B virus, was enrolled in the
French LTNP cohort (ALT ANRS CO15) in 1996. Briefly,
inclusion criteria in this cohort were HIV-1 seropositivity for at
least 8 years, stable CD4+ T-cell count (600 cells/mm3 over the
previous 5 years), no clinical symptoms, and no antiretroviral
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therapy. Patient 05005 was selected for the study because of the
presence of bNabs at entry in the cohort in a previous study
[40,13]. This patient had been followed up regularly several years
after enrollment, and before being treated. HIV-1 viral load (VL)
and CD4+ T cell counts during the 7 years follow-up are presented
in table 1. A regular decrease in CD4+ T cells and a slight but
regular increase of VL led to the introduction of antiretroviral
therapy (ART) in November 2001, 5 years and 9 months after
enrollment in the cohort. Stored peripheral blood mononuclear
cells (PBMC) were available at 6 time-points: 1996 (T0), 1997 (T1),
1998 (T2), 1999 (T3), 2000 (T4), and 2003 (T7). They were used
for DNA extraction and amplification of env sequences. Stored
serum samples were available at 3 time-points: 1996 (T0), 1998
(T2), and 2000 (T4). The latter were used for analysis of the
neutralizing antibody activity.
Cross-clade Neutralizing Activity
We previously observed that serum from patient 05005 at time
of entry into the ANRS CO15 cohort (T0, 1996) neutralized four
primary isolates of four different HIV-1 clades selected based on
their low sensitivity to neutralization [40,13]. These previous
neutralization experiments were carried out using the P4P cell line
Figure 1. Rooted phylogeny of the HIV-1 env sequences (gp120) obtained from PBMC of patient 05005. Codes of the different variants
are colored depending of time of sampling. Colored squares represent IC50 range of the thirteen pseudoviruses to the three sequential sera (from left
to right: S0, S2, S4). For clarity, color code was established: (green) IC50,1,000; (yellow) 1,000, IC50,5,000; (orange) 5000, IC50,10000; (red)
IC50.10,000. Node labels indicate the Bayesian posterior probability of the supported branch. Scale bar is expressed as number of nucleotides
substitutions/site.
doi:10.1371/journal.pone.0044163.g001
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(HeLa-CD4+-CXCR4+-CCR5+ cells) using an immunostaining
method for titration [45]. We have confirmed that this serum
collected at entry also neutralized additional primary isolates with
low sensitivity to neutralization, including four tier 2/3 reference
strains identified as indicators for cross-clade elite neutralization
[15,56]. These results were confirmed at T2 with similar
neutralization titers against these additional strains (Table 2).
Serum at T4 that was available in larger amounts allowed to test
the neutralizing activity of patient 05005 toward ten indicator
strains using the same assay. All ten primary isolates, representing
viruses of six clades (A, B, C, F, CRF01_AE, and CRF02_AG)
were neutralized with IC50 ranging from 55 to .540 (Table 2),
suggesting that patient 05005 presented a profile of elite
neutralizer.
Autologous Neutralizing Activity Against env
pseudoviruses
The autologous neutralizing activity was studied using pseudo-
typed viruses expressing selected gp120s. Sixty nine clones of the
env gene (1276 bp fragment encompassing most of the gp120
coding sequence) were obtained from the PBMCs collected during
the follow-up period (Table 1). Starting from 24 gp120-env clones
representative of the viral population’s diversity at the different
time-points, we obtained thirteen env pseudoviruses that were
infectious (Table 1; Figure 1). The autologous neutralizing activity
of the three available sequential sera was tested toward the 13 env
pseudoviruses. The env pseudoviruses displayed a broad range of
sensitivity to the autologous sera (Table 3). The most resistant env
pseudovirus was CL8 of T7 (T7-CL8), suggesting that T7-CL8
represented a late emerging variant that escaped the earlier
neutralizing response. Several late clones were however highly
sensitive to neutralization by antibodies present in earlier samples
(T7-CL4 and T7-CL6). Interestingly enough, we observed a
regular increase of neutralization potency of the sequential sera
toward 6 env pseudoviruses (T1-CL1, T1-CL3, T2-CL9, T3-CL7,
T4-CL3, T7-CL15) whereas the neutralization titers were stable
overtime for the others (Table 3). When aggregating the data, the
mean neutralization titers significantly increased from 6722 [95%
CI: 2746–10697] to 10233 [95% CI: 3336–17130] and 15065
[95% CI: 5911–24219] from T0 to T2 and T4, respectively
(p = 0.039, One way ANOVA test). This suggests that the
autologous neutralizing response continues to increase when
HIV continues to replicate, even in patients who already
developed broadly neutralizing antibodies.
Sensitivity of the env pseudoviruses to Human Broadly
Neutralizing Monoclonal Antibodies
Sensitivity to neutralization of the 13 env pseudoviruses was
analyzed using the following monoclonal antibodies (mabs): b12,
2G12, PG9 and PG16. A wide spectrum of sensitivity was
observed for each mab, without any clear evidence for temporal
relationship (Table 4). Clones with low sensitivity to b12, 2G12
and PG9 were already present in the early samples (T1 and
T2). However, two clones that appeared as the most resistant to
the neutralizing mabs tested (resistant to 2G12, PG9 and PG16)
were isolated from the late sample (T7-CL6 and T7-CL15).
This observation would need to be further studied using a
larger number of clones in order to get stronger data
concerning a possible evolution of the quasispecies toward
increased resistance to broadly active mabs. The 13 envelope
sequences did not carry any specific mutation in seven sites that
have been previously shown to impact b12 sensitivity [24].
Similarly, neither loss of potential N-glycosylation sites (PNGS)
at positions 156, 160 and 173 nor single mutations previously
shown to impact PG9 and PG16 sensitivity were observed
among the 13 variants [57–59]. In contrast, the three env
pseudoviruses that were 2G12-resistant (IC50.50 mg/mL) did
not harbor the PNGS at position N392 known to be essential
for the 2G12 epitope [26,42,60,61].
Phylogenetic Analyses
We used Bayesian Markov Chain Monte Carlo (MCMC)
inference to reconstruct the phylogeny of the viral population
found in patient 05005 and estimate divergence times within the
viral population. Since two recombination breakpoints were
identified in the entire set of the sixty-nine sequences (in the C2
region, from amino acids positions Y191 to P220 [HxB2 numbering]
and the C3 region from amino acids positions N340 to K362), we
have analysed the three sub-regions independently, and as well as
together. Although some differences in the branching patterns of
the reconstructed trees were observed, we found concordant
estimates between the partitioned data and global sequences for
both the time of the most recent common ancestor (tMRCA) and
mean rate of evolution of the population (data not shown). The
tMRCA of the 69 env sequences was estimated around September
1987 (95% Highest probability Density [HPD]: December 1982-
November 1991). This result was concordant with the patient’s
history, enrolled in the LTNP cohort in 1996 after a minimum of 8
years of infection. The estimated mean rate of evolution of the
viral population was 6.961023 nucleotide substitutions per site per
year [95% HPD: 4.8161023–9.3861023). Our estimate is also
consistent with previous rates of intra-host HIV-1 evolution [62].
The reconstructed phylogenies showed that the 69 env clones form
two distinct phylogenetic clusters diverging from the root,
suggesting either the initial transmission of two closely related
variants or an early selective process resulting in two co-dominant
variants (Figure 1 and 2). The phylogeny shows little chronological
organization. Sequences sampled at a given time point did not
form monophyletic clusters, but rather emerged from pre-existing
populations throughout the course of the infection (Figure 2). For
instance, some clones sampled at T7 (i.e. T7-CL4, T7-CL6 and
T7-CL11) shared a common ancestor with viruses sampled at T1
(i.e. T1-CL3), while others (i.e. T7-CL9, T7-CL12, T7-CL13, T7-
CL16 and T7-CL17) clustered with clone CL10 sampled at T2 (67
months earlier). This is suggestive of continuous re-emergence of
variants from viral reservoirs. Since the data were generated from
proviral DNA, sequences could be representative of either
circulating Envs at the time of sampling or archived proviral
sequences. However, the fact that the sequences collected at the
last time point (T7) were located on the longer branches of the
tree, indicative of a longer evolution, suggests that most of the
sequences were representative of circulating variants at the time of
sampling (Figure 1).
Env Evolution during the Follow-up
The estimated viral divergence over the 7 years of follow-up
showed that viral diversification continued in patient 05005 at the
chronic stage of infection. Based upon the mean number of
substitutions per site, we observed a continuous increase of viral
divergence through time ranging from 0.054 (95% CI: 0.049–0.06)
substitutions/site at T0 to 0.108 (0.099–0.116) substitutions/site at
T7 (Table 1; Spearman r test = 0.97, p = 0.017). Previous studies
reported a global increase in gp120 length over time, particularly
in variable regions, and in the number of PNGS during the course
of infection, suggesting that these mechanisms support escape to
neutralizing antibodies [10,63,64]. In our study, neither the length
of both gp120 and variable regions, nor the number of PNGS
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increased during the 7 years follow-up (Table 1). Similarly, we did
not observe any significant net charges in amino acid substitution
over the course of infection, considering either the entire gp120
sequences or the variable regions (Table 1). Analysis of viral
diversity among the sixty-nine sequences showed that the variable
regions as well as the C3 region were highly variable among the 69
clones, mean entropy varying from 0.063 (95CI: 0.043–0.083) in
constant regions to 0.307 (95% CI: 0.281–0.334) in variable
regions, with an intermediate value (0.230; 95% CI: 0.173–0.286)
in the C3 region (Figure 3).
We tried to identify selective pressures that may have shaped
genetic variation among all clones. dN/dS ratios from the
successive time points were calculated for each constant and
variable region. Except for the last time point, non synonymous
(N) and synonymous (S) substitution rates did not increase over
time, varying respectively from 4.1% to 4.8% and 5.2% to 6.1% of
the overall rate of substitutions. Clones isolated at T7 presented a
significant higher diversity, considering both N (6.2%) and S
(7.7%) substitutions. When considering the full length gp120
sequences, we have found no evidence of clear positive selection
(expressed as dN/dS.1), irrespective of the time point (mean dN/
dS varying from 0.79 at T4 to 1.02 at T3).
The evolution of gp120 was illustrated by numerous single
amino acids (AA) substitutions both in variable and constant
regions. Among these numerous substitutions, we identified 33
positively selected codons using the Bayes Empirical Bayes (BEB)
analysis implemented in codeML (cut-off posterior probability
P.95%; Figure 4). These results were confirmed with a model-test
comparison: M8 (positive selection model) had a significantly
better fit to the data than M7 (neutral model) (p,0.05). Positive
selection pressure was observed both in variable and constant
regions (particularly C3), suggesting that these regions are
probably targets of the adaptative immune response. Considering
AA substitutions among the 33 positively selected codons, we
showed a continuous evolution overtime, even at the last time-
point. Figure 4A illustrates the ratio of original AA (in blue) and
variant AA (in red) at the different time-points at each of these
positions. For instance, it shows that the variant AA at position 84
in C1 that was present in 30% of clones at T0 was found in 100%
of clones and T4 and T7. A synthetic analysis of the evolution at
the 33 positions is shown in figure 4B which indicates that the
percentage of original AA at these positions decreased regularly
overtime, from 67.7% to 37.5% from T0 to T7 (Figure 4B,
R2= 0.85). If some (5/33) AA substitutions observed during the
follow-up reverted, most did not and became dominant (20/33).
Of note is the fact that the 3 substitutions that were found in all the
clones of the two late samples (T4 and T7) were located in
constant regions (V84I in C1, K241N in C2 and R344Q in C3),
suggesting that they might be associated with a biological
advantage.
Phylogenetic Analysis, Selective Pressure and
Neutralizing Activity
Trying to link the phenotypic properties to the genotypic
properties, we analyzed whether the level of sensitivity to
autologous neutralization of each of the thirteen infectious clones
would be associated with specific genetic features. We did not
observe a strong clustering of sensitive or resistant env pseudo-
viruses in specific branches of the tree (Figure 1).
More in depth, we asked whether positively selected AA could
be associated to sensitivity to autologous neutralization. Not a
single AA substitution by itself clearly predicted a change in
sensitivity to autologous neutralization. We therefore tried to
identify whether any signature pattern (i.e. any combination of AA
substitutions among the 33 positively selected codons) would be
associated with sensitivity to autologous neutralization. To that
purpose, we ranked the 13 pseudoviruses according to their mean
sensitivity to autologous neutralization (Figure 5). Then, we
compared the sequence of the most resistant env pseudovirus
(T7-CL8) to that of the most sensitive env pseudovirus (T3-CL7),
and we performed successive analyses by adding one by one
Table 2. Cross-neutralizing activity of sera from patient 05005.
Serum Year Clade B Clade A Clade C Clade F CRF01_AE CRF02_AG
FRO BIG 92BR020 94UG103 92RW020 93IN905 GIL MBA 92TH021 KON
T0 1996 Pos NA .540 207 285 .540 Pos Pos .540 Pos
T2 1998 NA NA .540 349 357 .540 NA NA .540 NA
T4 2000 .540 .540 .540 153 315 .540 .540 206 .540 55
Values correspond to IC50. NA: not available. POS: presence of Nab identified previously using a different assay [13,36].
doi:10.1371/journal.pone.0044163.t002
Table 3. Autologous neutralizing activity of sera from patient 05005.
Serum Year 1997(T1) 1998(T2) 1999(T3) 2000(T4) 2003(T7) Mean IC50 (CI95%)
CL1 CL3 CL5 CL9 CL10 CL7 CL1 CL3 CL4 CL6 CL8 CL13 CL15
T0 1996 3099 3142 1684 2748 7477 9000 14880 4073 22561 13382 430 1548 3357 6722 (2746–10697)
T2 1998 3040 2265 1598 6692 6490 43066 13222 5276 17704 16422 869 3440 12940 10233(3336–17130)
T4 2000 17989 5229 1514 22217 7551 56216 7703 8927 21398 16025 643 2510 27924 15065 (5911–24219)
Mean IC50 8043 3545 1599 10552 7173 36094 11935 6092 20554 15276 647 2499 14740
The autologous neutralizing activity was evaluated toward thirteen pseudoviruses issued from 5 time-points (1997 to 2003). Values correspond to IC50 serum titers.
Mean IC50 is indicated for each clone. Mean IC50 and 95% confidence interval (CI 95%) are indicated for each serum.
doi:10.1371/journal.pone.0044163.t003
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sequences of the subsequent most resistant env pseudovirus (T2-
CL5, T7-CL13, …) versus the subsequent most sensitive (T7-CL4,
T7-CL6, …) env pseudovirus. Considering only the 3 most sensitive
clones (T3-CL7, T7-CL4 and T7-CL6 with mean IC50 range from
15276 to 36094) and the three most resistant clones (T2-CL5, T7-
CL8 and T7-CL13 with mean IC50 range from 647 to 2499), we
identified 5 AA positions that could be associated with sensitivity
to autologous neutralization (Figure 5). They were located in V3,
C3 and V5 regions. The most sensitive env pseudoviruses presented
the sequence V319R/K355R/W429Q460G/T463 whereas the most
resistant viruses had the sequence I/S319T355G429E460E463
(Figure 5). The potential impact of these variations was
strengthened by net charges changes for three of them (R/
K355T, Q460E and G/T463E).
Discussion
Recent investigations of the genetic diversity of HIV-1 at
transmission and of the evolution of the virus during the early
phases of infection have provided critical insights into the
immunovirological mechanisms that take place in the earliest
stages of HIV-1 infection [31,33,35,65–69]. Several studies
allowed the identification of adaptive changes that enable escape
from immune responses, particularly escape from neutralizing
antibodies during the early phases of HIV-1 infection [8–10,70].
They clearly demonstrated the continuous escape to autologous
neutralizing antibodies. However, autologous antibodies have a
narrow spectrum of neutralization, restricted to the subject’s own
virus. While all these studies focused on the early phases of HIV-1
infection, we wanted to document the late, rather than early,
evolution –if any- of HIV-1 in presence of broadly cross-
neutralizing antibodies. Identifying the mechanism of escape to
bNabs would be an additional element useful for vaccine
designers. Our study was made possible through the follow-up of
a LTNP patient who was identified more than 8 years after
seroconversion while having already developed broadly neutral-
izing antibodies [40,13]. Based on additional neutralization assays
using ten primary isolates of six different clades selected based on
their moderate (tier 2) or low (tier 3) sensitivity to neutralization,
we first confirmed in the present report that this patient might be
considered as an elite neutralizer. Indeed, his serum both at entry
in the LTNP cohort, more that 8 years post-infection, and several
years later, neutralized all the viruses tested including strains
identified previously as indicators of elite neutralization [15].
Sixty-nine env clones (gp120 region) were obtained from PBMC
DNA at six time points starting from the entry in the cohort in
1996 up to 7 years later. Using Bayesian MCMC inference, we
estimated the time of infection of patient 5005 around 1987 (95%
CI: December 1982 to November 1991), nine year before entry in
the cohort, confirming the recorded clinical history. We therefore
estimate that the entire analysis that we performed has
corresponded to a sixteen years duration of HIV-1 infection.
Evidence of ongoing viral evolution was found in our LTNP
patient, supported by both the phylogenetic analyses that showed a
continuous diversification and an increasing divergence over time,
as it was previously described by Shankarappa et al., albeit on a
shorter duration (6–12 years) of follow-up [71].
For the first time to our knowledge, we show in this report that
autologous neutralizing activity may still continue to increase over
time more than 10 years after infection. This was illustrated by the
fact that we observed a regular increase of autologous neutrali-
zation potency of the sequential sera toward infectious pseudo-
typed viruses issued from the various time points. However, due to
the polyclonal nature of antibodies present in the serum samples,
we do not know whether the neutralizing antibodies that were
specific for the patient’s envelopes were those capable of cross-
neutralization. Interestingly, the most resistant pseudotyped virus
was issued from the last visit sample. This suggests that this variant
represented a late emerging escape variant and, additionally,
provides phenotypic evidence of ongoing viral evolution approx-
imately 16 years post-infection. Taken together, these data
indicate first that HIV-1 continues to evolve in vivo more than
ten years after infection even in presence of both autologous Nabs
and heterologous bNabs. This means that, albeit the presence of
cross-clade bNabs that are supposed to target conserved epitope(s),
HIV-1 is still able to evolve to bypass this blockade. A similar
observation of late continuous evolution and escape was recently
reported in a patient who developed bNabs to the CD4-binding
site [72]. Secondly, we show that neither a continuous increase of
autologous Nabs nor the presence of bNabs seem to allow the
control of the patient’s clinical evolution, since a regular increase
of virus load and a regular decrease of CD4+ T-cell counts led to
the introduction of antiretroviral treatment five years after entry in
the cohort. Our observation does not support previous findings
who suggested that there may be limits to the capacity of HIV-1 to
evolve continuously in response to Nabs and that the Nab response
may contribute to the long-term control of HIV [3,39]. Of note
also is the fact that variants present at a given time point display a
wide diversity in sensitivity to autologous neutralization, as
previously reported by others [3].
A wide spectrum of sensitivity to broadly active mabs was
observed among the pseudotyped viruses that we generated. Two
clones that appeared as the most resistant to the neutralizing mabs
were isolated from the late sample, suggesting that further studies
using a larger number of clones would deserve to be done to
answer the question of a possible intra-host evolution of HIV-1
toward increased resistance to broadly active mabs. Interestingly,
these two late clones were resistant to the 3 mabs that target
glycan-dependent epitopes.
Many reports have shown that neutralization escape to Nabs is
often associated with longer variable loops and increased number
of PNGS [10,32,63,64,73,74]. We did not observe any significant
Table 4. Sensitivity to neutralization by human broadly
neutralizing monoclonal antibodies of the Env clones issued
from patient 05005.
IC50 (mg/mL)
b12 2G12 PG9 PG16
CL1T1 13.86 11.40 0.02 0.02
CL3T1 0.21 1.35 1.80 0.11
CL5T2 2.88 14.10 1.02 0.12
CL9T2 0.11 0.36 .10 0.26
CL10T2 ,0.02 0.62 .10 0.34
CL7T3 ,0.02 .50 0.91 0.28
CL1T4 .50 1.85 0.07 0.02
CL3T4 0.15 0.90 .10 2.67
CL4T7 ,0.02 1.58 0.28 0.08
CL6T7 0.07 .50 .10 .10
CL8T7 1.29 1.72 0.71 0.07
CL13T7 0.16 14.5 6.52 0.27
CL15T7 0.02 .50 .10 .10
doi:10.1371/journal.pone.0044163.t004
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change over time neither in variable loops length nor number of
PNGS in the gp120 sequences obtained from the sequential
samples of our patient. It could be argued that in contrast to our
study, most of the previous observations were performed in
samples collected during the early years post-infection in each case
and that these properties may be signatures of early escape.
Therefore, other mechanisms may be involved in late neutraliza-
tion escape. We cannot exclude that such increase in variable
loops lengths and number of PNGS occurred in our patient but
had reached a plateau before entry in the cohort.
We identified 33 positively selected codons across gp120,
including four in C1, three in C2, six in C3 and one in C4.
Particularly, the implication of the C3 region was confirmed by the
analysis of diversity using Entropy-One software. The role of the
third constant region of gp120 in neutralization escape was already
emphasized in previous studies, in viruses of both clades B and C
[27,28,74–76]. Acquisition of positively selected AA and their
conservation over time suggested their implication in env viral
escape. In contrast, reversions of single substitutions observed in
several positions at the last time-points may be indicative of
constraints on the env region to maintain viral fitness. Finally, we
tried to identify sequence signatures that would be associated with
escape to neutralization in our particular case of late escape.
Recent studies reported original computational methods useful to
define molecular signatures that correlate with neutralization
phenotype [24]. They allowed for instance to identify a three-
amino-acid substitution pattern in V4 of subtype C viruses that
was associated with greater neutralization potency [77]. We
therefore tried to identify whether any signature pattern among
the 33 positively selected codons would be associated with
sensitivity or resistance to autologous neutralization. Not a single
AA substitution by itself clearly predicted a change in sensitivity to
autologous neutralization. However, we identified five amino acids
whose variation may impact neutralization and might be
associated with escape to bNabs in our patient. They were located
in V3, C3 and V5 regions, and the potential impact of these
variations was strengthened by net charges changes for three of
them (R/K355T in C3, Q460E and G/T463E in V5).
One limitation of our study is that we analyzed the evolution of
the virus based on DNA sequences present in PBMC. It is usually
considered that plasma RNA gives a more accurate picture of the
viral population at time of sampling than viral DNA, since proviral
DNA contains a significant fraction of archived sequences from
earlier times. This has been shown in elite suppressors [78,79] and
in patients receiving highly active antiretroviral treatment [80,81].
However, several studies clearly indicated that sequences obtained
at subsequent time points from plasma RNA and PBMC proviral
DNA of a given untreated individual form a single virus
population at most time points, therefore allowing evolutionary
studies of viral sequences from different sources [71,82,83]. A
second limitation may have been due to the introduction of an
antiretroviral treatment in our patient in 2001, two years before
the last sample that we explored. However, if this treatment should
have slow down the evolution of the virus during the last two years
of our follow up, this was not visible through the biological data
since the plasma viral load was still detectable in 2003 (T7:852
copies/mL) and the molecular analyses clearly showed a
continuous evolution at T7 (Table 1). A third limitation may be
linked to the strategy used to produce the pseudotyped viruses.
Indeed, the sequences were not obtained using the single genome
amplification technology that is considered as a gold standard to
avoid recombination events during the PCR from bulk DNA, and
the pseudotyped particles harbored chimeric envelopes composed
of each gp120 associated with NL4.3 gp41. Although we cannot
exclude that this heterologous association had effects on the
sensitivity to neutralization by antibodies directed to gp120, one
advantage was that all the chimeric envelopes were generated
Figure 2. Time-scaled phylogenetic tree of HIV-1 env sequences (gp120) obtained from PBMC of patient 05005. Codes of the different
variants are colored depending of time of sampling. X axis figures time as measured in years before the most recently sampled patient sequence.
Branch nodes indicates estimated dates.
doi:10.1371/journal.pone.0044163.g002
Figure 3. Entropy plot of the 69 env sequences. Evaluation of the amino-acid variations among the 69 clones over the gp120 envelope.
Constant and variable regions are indicated on top. Variable regions are highlighted in light grey. C3 constant region is also highlighted in light grey.
doi:10.1371/journal.pone.0044163.g003
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similarly limiting the variability due to the diversity of gp41
sequences.
Conclusions
In conclusion, we have shown through the reported case that
HIV-1 may continue to evolve in presence of both broadly
neutralizing antibodies and increasing autologous neutralizing
activity more than 10 years after infection. Such clinical material
may provide unique opportunities to reveal the mechanisms and
the molecular determinants of escape of HIV-1 to the most potent
broadly cross-neutralizing antibodies. Continued study of HIV-1
evolution in similar exceptional situations may help to refine the
design of relevant vaccine immunogens.
Figure 4. Evolution of the 33 positively selected codons over time. (A) Each bar represents the percentage of original dominant AA (in blue)
and the percentage of variant AA (in red). Positions refer to HxB2 numbering. (B) Evolution of the percentage of original AA over time. Results are
shown as distribution of these percentages for each time point. For each distribution, the horizontal lines represent the 10th, 25th, 50th (median), 75th
and 90th percentiles. Mean value and 95% confidence intervals (CI 95%) are indicated at the top of each box.
doi:10.1371/journal.pone.0044163.g004
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